Comments
Loading...

Karyopharm Therapeutics Stock Guidance

KPTINASDAQ
Logo brought to you by Benzinga Data
$5.97
At close: Apr 24 EDT
$5.98
0.010.17%
Pre-Market: 4:17 PM EDT

Karyopharm Therapeutics Stock Guidance | NASDAQ:KPTI | Benzinga

Karyopharm Therapeutics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.

Get Alert
02/19/2025KPTI
Karyopharm Therapeutics
FY2025———$140.00M$155.00M$165.50MGet Alert
01/13/2025KPTI
Karyopharm Therapeutics
FY2024———$145.00M$145.00M$152.89MGet Alert
01/13/2025KPTI
Karyopharm Therapeutics
Q42024———$30.00M$30.00M$38.20MGet Alert
11/05/2024KPTI
Karyopharm Therapeutics
FY2024———$145.00M$155.00M$152.35MGet Alert
08/06/2024KPTI
Karyopharm Therapeutics
FY2024———$145.00M$160.00M$145.44MGet Alert
05/08/2024KPTI
Karyopharm Therapeutics
FY2024———$140.00M$160.00M$146.52MGet Alert
02/29/2024KPTI
Karyopharm Therapeutics
FY2024———$140.00M$160.00M$152.02MGet Alert
01/08/2024KPTI
Karyopharm Therapeutics
Q42023———$33.60M$33.60M$37.64MGet Alert
01/08/2024KPTI
Karyopharm Therapeutics
FY2023———$146.00M$146.00M$150.03MGet Alert
11/02/2023KPTI
Karyopharm Therapeutics
FY2023———$145.00M$160.00M$151.17MGet Alert
08/02/2023KPTI
Karyopharm Therapeutics
FY2023———$145.00M$160.00M$150.34MGet Alert
05/04/2023KPTI
Karyopharm Therapeutics
FY2023———$145.00M$160.00M$157.37MGet Alert
02/15/2023KPTI
Karyopharm Therapeutics
FY2023———$160.00M$175.00M$163.24MGet Alert
01/09/2023KPTI
Karyopharm Therapeutics
Q42022———$34.20M$34.20M$38.13MGet Alert
01/09/2023KPTI
Karyopharm Therapeutics
FY2022———$157.70M$157.70M$161.68MGet Alert
11/03/2022KPTI
Karyopharm Therapeutics
FY2022———$155.00M$165.00M$157.23MGet Alert
08/04/2022KPTI
Karyopharm Therapeutics
FY2022———$155.00M$165.00M$160.03MGet Alert
01/11/2021KPTI
Karyopharm Therapeutics
FY2020———$108.00M$109.00M$98.14MGet Alert
01/11/2021KPTI
Karyopharm Therapeutics
Q42020———$35.00M$36.00M$24.91MGet Alert

FAQ

Q

What is the most recent guidance for Karyopharm Therapeutics (KPTI)?

A

There have been no specific sales or earnings guidance reported for Karyopharm Therapeutics in recent months.

Browse guidance and forecast on all stocks.

People Also Watch